Latest News - Verbund AG
Top Corporates Hub
Verbund AG
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110
07.10.2026 08:40
Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
05.10.2026 10:00
IRVINE, Calif., October 05, 2026--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team.
Nike, Synaptics And 3 Stocks To Watch Heading Into Friday
02.10.2026 04:16
Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
17.09.2026 11:02
Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound
07.09.2026 03:10
Baron Asset Fund initiated a position in Edwards Lifesciences due to its dominant heart valve market share. Read the full analysis for more details.
Insider Move: Daveen Chopra Exercises Options, Realizing $551K At Edwards Lifesciences
27.08.2026 11:02
Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on
Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match
04.08.2026 15:17
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
30.07.2026 14:33
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Edwards Lifesciences (EW) Stock Looks Fair On Cash Flow While Earnings Trade At A Premium
25.07.2026 05:11
Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and ...
24.07.2026 05:00
Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $95
16.07.2026 11:59
Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $90 to $95.
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110
13.07.2026 10:15
RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $100 to $110.
BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $110
30.06.2026 07:56
BTIG analyst Marie Thibault maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $100 to $110.
Edwards Lifesciences (EW) Is Up 6.2% After New TAVR Data at New York Valves Conference
30.06.2026 00:15
In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing evidence across its aortic, mitral and tricuspid transcatheter valve therapies, including PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and SAPIEN M3 programs. An important takeaway is how the PROGRESS trial’s baseline data on moderate aortic stenosis and long-term durability findings for SAPIEN 3 deepen understanding of earlier, less invasive treatment options for complex...
Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
26.06.2026 14:15
NEW YORK, June 26, 2026--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
CardioMech Shareholders Appoint Ramin Mousavi as Chairman of the Board
24.06.2026 10:01
Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced the appointment of Ramin Mousavi as Chairman of the Board, effective immediately.
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
22.06.2026 14:28
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Should You Continue to Hold EW Stock in Your Portfolio?
12.06.2026 12:31
Edwards gains from strong TMTT growth, RESILIA adoption and expanding TAVR use, but macro pressures and currency swings remain key risks.
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
04.06.2026 15:30
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TD Cowen Maintains Buy on Edwards Lifesciences, Raises Price Target to $104
02.06.2026 10:53
TD Cowen analyst Joshua Jennings maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $97 to $104.